Adrenal incidentaloma's: are lessons still to be learned?
Sir, The widespread use of imaging procedures has led to an increased discovery of incidental masses in the adrenal glands. The probability of finding an adrenal adenoma on abdominal computed tomography (CT) increases with age and is $0.2 % in 20-29 years age group as compared to 7% in the elderly people. 1, 2 Although the majority of these incidentaloma's are non-functioning benign adenoma's but their increased prevalence poses a diagnostic and therapeutic challenge. The natural history of adrenal incidentaloma's is yet to be clearly defined as they may present at a later date as cortisol secreting adenomas, pheochromocytoma, adrenal cortical carcinoma and metastatic carcinoma. This possibility of conversion from a non-secreting state to an autonomous hypersecretory tumor is low but careful assessment and vigilance is needed with timely follow-up for early diagnosis. We present one such patient who had a benign adenoma at presentation but went on to develop an adrenal cortical carcinoma with metastases leading to severe challenges in management.
Case
A 50-year-old female patient was presented to the gynaecologist in February 2007 with complaints of menorrhagia. An ultrasound of abdomen not only confirmed a fibroid of the uterus but also showed a doubtful shadow in the left adrenal gland. This was followed with a CT scan that showed an adrenal adenoma of 3.5 Â 3 cm with no adjoining lymphadenopathy or ascites. The patient was normotensive and her serum potassium was normal. She was referred to us for evaluation and we proceeded to do further investigations. Her overnight dexamethasone suppression tests showed a serum cortisol of 71 nmol/l but a 24 h urine-free cortisol and urine catecholamines was normal on three occasions, which was performed over a period of 1 month. An aldosterone renin ratio was estimated after appropriate measures and this confirmed a normal value as well. Her urine catecholamines were again repeated in couple of month's time and this was normal again on two occasions. It was then concluded that this patient had a benign non-secreting adenoma of her left adrenal gland that was picked up 'incidentally' while being investigated for a fibroid uterus. She went on to have a hysterectomy with bilateral salpingo-oophorectomy and was commenced on hormonal replacement therapy but was assigned an endocrine follow-up in about 6 months time.
She returned to the clinic in October 2007 for a follow-up CT scan, which now showed that the adrenal mass has now grown in size and measured 4.4 cm with well-defined sharp borders. Surprisingly, no comment was made about an unenhanced CT attenuation value and a contrast medium washout was not performed. Her urine catecholamines were repeated and it returned as normal again. In view of the size of the adenoma, the patient was discussed with the endocrine surgeons and the patient went on to have a laparoscopic left adrenalectomy in May 2008. Histology of the mass showed element of abnormal cells with evidence of necrosis and vascular invasion within the tumor.
A CT scan was repeated in October 2008 that showed a new lobulated solid soft tissue mass of 2 Â 2 cm in the left adrenal bed with low regional lymph nodes with encasement of the left adrenal artery. The patient started to show a cushingoid appearance and a random cortisol of 754 nmol/l with low potassium of <3.5 mmol/l was recorded. She was commenced on ketoconazole and was referred to the oncologists for further management of her locally advanced adrenal cortical carcinoma with regular follow-up at endocrine clinic as well. In the next few months, she went on to have several cycles of chemotherapy with carboplatin and etoposide followed with mitotane and insulin like growth factor 1 receptor/insulin receptor (IGF-1R/IR) tyrosine kinase inhibitor (trial drug). The situation was complicated with significant cushingoid appearance, persistent high blood pressure, low potassium and massively increased levels of serum cortisol in excess of 4000 nmol/l on multiple occasions. She needed a few hospital admissions to correct her anaemia and hypokalemia, and was on potassium supplements, metyrapone, lisinopril and spironolactone at that point.
The response to different cycles of chemotherapy was quite indifferent and she became more and more unwell in the next few months with development of metastasis in her left neck, liver, spleen, left lateral abdominal wall and urinary bladder with development of malignant pleural effusion and ascites and widespread abdominal lymphadenopathy. Hypokalemia was a persistent problem despite maximum measures and she was eventually referred for palliative care in October 2009. She deteriorated further in next 2 months and died in December 2009.
Discussion
The discovery of clinically inapparent adrenal masses while imaging the abdomen for other purposes has often led to a clinical dilemma. 3 The challenge lies in establishing the clinical features, hormonal status and management plan in patients with adrenal hyper function and malignant disease. 4, 5 The true prevalence of adrenal incidentalomas (AIs) is unknown but autopsy series shows prevalence from 1.4% to 2.9-6.0%, 6 whereas in CT scan studies it ranges from 0.6% to 1.9%. 6, 7 The prevalence of AIs increases with age recorded to be $7% in fifth and seventh decades with a peak incidence in the sixth decade. 8 Clinically inapparent adrenal masses are nonfunctioning in about 70% of cases but 5-10% may be characterized by autonomous glucocorticoid production leading to subclinical hypercortisolism (SCS). 9 Approximately 5% of AIs are proved to be pheochromocytomas, 1% as aldosterone producing adenomas, whereas sex hormone secreting adrenocortical tumors are rare and typically has clinical features of androgen or oestrogen excess. 1 Adrenal cortical carcinoma (ACC) is a rare malignancy (incidence of 1-2 per million people) 10 and the prevalence is clearly related to the size of the tumor. ACC accounts for 2% of tumors that are !4 cm, 6% of tumors that are 4.1-6 cm and 25% of tumors that are 46 cm. 11 The cornerstone in management of AIs is assessing them for hormone hypersecretion and monitoring them for potential malignant transformation. The transformation rate for small non-secretory masses (<3 cm) to functional tumors is low but chances are more in bigger masses and the risk for malignancy is 1 out of 1000. 9 The size of the mass and its appearance are important predictors of malignancy and they also influence the tumor staging and the overall prognosis. 12, 13 ACC is more common in women than men (ratio 1:5) 14 and the age distribution shows a bimodal peak in childhood and in fourth and fifth decade. 15 Patients may either present with inactive masses (usually larger ones) with abdominal discomfort, weight loss or anorexia, but the majority (60%) presents with evidence of adrenal steroid hormone excess in the form of rapidly progressing Cushing's syndrome with or without features of virilisation. 13 Altered menstrual pattern, abnormal libido, gynaecomastia and hypokalemia related symptoms is also encountered. 9, 13 Serial evaluation of hormonal status is mandatory to evaluate hormone hypersecretion in ACC as in our patient who was completely asymptomatic initially but progressed to develop symptoms and complications related to hormone excess. An overnight dexamethasone (1 mg) suppression test should be performed along with measurement of fractionated metanephrines and catecholamines in a 24-h urine specimen. Co-existent hypertension and hypokalemia warrants estimation of plasma aldosterone concentration and plasma renin activity. 3 CT scan is the cornerstone for imaging the adrenals in cases of incidentalomas to evaluate the possibility of a existing neoplasm in relation to its size, homogeneity, presence of necrosis and calcifications and extent of invasion. 16 The available data usually suggest that nearly all lesions <4 cm in size are usually benign. 9 Change in the size and shape of the lesion is a useful indicator of malignancy, which was noticed in our patient as adenomas are slowly growing and tend not to change size. A standardized measure of radiograph absorption on an unenhanced CT expressed as Hounsfield units (HU) and measurement of rapidity of washout of contrast medium on delayed contrast enhanced CT are important techniques to differentiate between a benign and malignant lesion, 3, 16 especially when the size is changing in follow-up scans.
Unfortunately due to lack of proper communication this was not performed in our patient, which would have provided valuable information. Benign lesions usually have attenuation on unenhanced CT 10 HU with rapidity of washout of contrast medium !50% at 10 min. The figures for an ACC would have been an attenuation (density) of 410 HU on unenhanced CT and an washout of <50% of the contrast medium at 10 min. Magnetic resonance imaging and positron emission tomography scans with 18 flurodeoxyglucose are also available for evaluation of incidental adrenals masses. Imaging guided fine needle aspiration biopsy is also useful for diagnosing primary and metastatic lesions but pheochromocytomas should be ruled out before attempting to do it to avoid a crisis.
The optimal management for AIs is usually a surgical removal (either open or laparoscopic) but the decision is often based on multiple considerations principally involving the clinical condition and personal concerns of individual patients. Lesions <4 cm which are hormonally inactive and defined as low risk by imaging criteria are usually not resected but strategic follow up should be in place. Two percent of lesions of this size can represent a primary ACC and those demonstrating suspicious features should be removed. 3, 6, 17 Excision is strongly supported for lesions 46 cm in diameter but for masses between 4 and 6 cm either a close follow-up or a surgical removal are regarded as reasonable choices. 6, 9 Operative interventions are also the treatment of choice in patients with pheochromocytoma and aldosteronomas but the debate still exists for patients with SCS. 3, 6, 9 In patients with primary ACC as our patient radical excision with en bloc resection of local invasion is the treatment of choice in early part of the disease. Hormone excess frequently adds to the disease burden and is usually managed with adrenostatic drugs like ketoconazole, metyrapone, aminoglutethimide and etomidate. 13 Metastatic and recurrent disease usually need combination chemotherapy or local radiotherapy. Modern treatments like anti-angiogenic agents, tyrosine kinase inhibitors, gene therapy and immunotherapy are also considered as important options.
18
The design to follow-up for patients with AIs is usually made to detect change in tumor size and evaluate changes in its secretory state. Over the years, the size may either increase or decrease; 3, 19 hence, in patients with stable tumor size on two imaging studies done at least 6 months apart with no exhibition of hormone hyper secretion over 4 years, further follow-up is usually not required. 9 Hormone excess may develop in 20% patients during follow-up but unlikely in patients with lesions <3 cm so less frequent imaging is needed. 3, 9 However, an earlier (3 months) and frequent follow-up is needed for patients with suspicious imaging phenotype. 19 For patients with primary ACC who have undergone resection follow-up for hormonal markers should be measured for detecting recurrence, although CT is more sensitive and restaging CT is mandatory at intervals of 3 months for the first 2 years. 13 In summary, we would say that as AIs are diagnosed with increasing frequency in present day clinical practise and a careful and methodical approach should be attempted in evaluation of these masses. Hormonal studies and imaging techniques are essential in categorizing these tumors to be benign and non-secretory or as malignant/hormonally active. Surgical removal is mandatory in large and suspicious masses with or without hypersecretory states but careful follow up is needed for masses of smaller size and those which are hormonally inactive to detect any potential change of status in the future period. Finally, an effective communication should exist between endocrinologist, radiologist and surgeons who are dealing with these patients. 
